<?xml version='1.0' encoding='utf-8'?>
<document id="23251210"><sentence text="Prolonged Drug-Drug Interaction between Terbinafine and Perphenazine."><entity charOffset="40-51" id="DDI-PubMed.23251210.s1.e0" text="Terbinafine" /><entity charOffset="56-68" id="DDI-PubMed.23251210.s1.e1" text="Perphenazine" /><pair ddi="false" e1="DDI-PubMed.23251210.s1.e0" e2="DDI-PubMed.23251210.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23251210.s1.e0" e2="DDI-PubMed.23251210.s1.e1" /></sentence><sentence text="I report here an elderly woman receiving perphenazine together with terbinafine"><entity charOffset="41-53" id="DDI-PubMed.23251210.s2.e0" text="perphenazine" /><entity charOffset="68-79" id="DDI-PubMed.23251210.s2.e1" text="terbinafine" /><pair ddi="false" e1="DDI-PubMed.23251210.s2.e0" e2="DDI-PubMed.23251210.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23251210.s2.e0" e2="DDI-PubMed.23251210.s2.e1" /></sentence><sentence text=" After 1 week of terbinafine treatment she experienced extrapyramidal symptoms and, in particular, akathisia"><entity charOffset="17-28" id="DDI-PubMed.23251210.s3.e0" text="terbinafine" /></sentence><sentence text=" Her symptoms did not disappear for 6 weeks, and so at 2 weeks prior to this most recent admission she had stopped taking terbinafine"><entity charOffset="122-133" id="DDI-PubMed.23251210.s4.e0" text="terbinafine" /></sentence><sentence text=" However, these symptoms persisted for 3 weeks after discontinuing terbinafine"><entity charOffset="67-78" id="DDI-PubMed.23251210.s5.e0" text="terbinafine" /></sentence><sentence text=" It is well known that terbinafine inhibits CYP2D6 and that perphenazine is metabolized mainly by CYP2D6"><entity charOffset="23-34" id="DDI-PubMed.23251210.s6.e0" text="terbinafine" /><entity charOffset="60-72" id="DDI-PubMed.23251210.s6.e1" text="perphenazine" /><pair ddi="false" e1="DDI-PubMed.23251210.s6.e0" e2="DDI-PubMed.23251210.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23251210.s6.e0" e2="DDI-PubMed.23251210.s6.e1" /></sentence><sentence text=" Thus, when terbinafine and perphenazine are coadministrated, the subsequent increase in the concentration of perphenazine may induce extrapyramidal symptoms"><entity charOffset="12-23" id="DDI-PubMed.23251210.s7.e0" text="terbinafine" /><entity charOffset="28-40" id="DDI-PubMed.23251210.s7.e1" text="perphenazine" /><entity charOffset="110-122" id="DDI-PubMed.23251210.s7.e2" text="perphenazine" /><pair ddi="false" e1="DDI-PubMed.23251210.s7.e0" e2="DDI-PubMed.23251210.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23251210.s7.e0" e2="DDI-PubMed.23251210.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23251210.s7.e0" e2="DDI-PubMed.23251210.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23251210.s7.e1" e2="DDI-PubMed.23251210.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23251210.s7.e1" e2="DDI-PubMed.23251210.s7.e2" /></sentence><sentence text=" Thus, terbinafine therapy may be associated with the induction and persistence of extrapyramidal symptoms, including akathisia"><entity charOffset="7-18" id="DDI-PubMed.23251210.s8.e0" text="terbinafine" /></sentence><sentence text=" This case report emphasizes the importance of monitoring drug-drug interactions in patients undergoing terbinafine and perphenazine therapy"><entity charOffset="104-115" id="DDI-PubMed.23251210.s9.e0" text="terbinafine" /><entity charOffset="120-132" id="DDI-PubMed.23251210.s9.e1" text="perphenazine" /><pair ddi="false" e1="DDI-PubMed.23251210.s9.e0" e2="DDI-PubMed.23251210.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23251210.s9.e0" e2="DDI-PubMed.23251210.s9.e1" /></sentence><sentence text="" /></document>